[Genomic alterations in thymic epithelial tumors: State of knowledge, and the interest of liquid biopsy].

Authors

A Chour, N Beljebbar, L Rivard, L Chalabreysse, M Duruisseaux, T Pierret

Published in

Revue des maladies respiratoires. Oct 26, 2026. Epub Oct 26, 2026.

Abstract

In the absence of randomized phase III trial data, thymic epithelial tumors (TETs) are rare malignancies of the prevascular mediastinum managed according to the WHO histological and the Masaoka-Koga classifications.
Next-generation sequencing has revealed distinct mutational characteristics between thymomas, which are characterized by a low tumor mutational burden and a near-specific GTF2I mutation, and thymic carcinomas which are dominated by alterations in CDKN2A, TP53 and KIT. These findings open the way for novel therapeutic strategies, involving immune checkpoint inhibitors and multi-kinase inhibitors in advanced thymic carcinomas. Notwithstanding the potential of liquid biopsy as a non-invasive monitoring tool, specific biological obstacles in TETs currently limit its clinical applicability.
Recent confirmation of the interest of liquid biopsy in perioperative management of lung cancer raises the prospect of transferring this approach to TETs. The key challenge lies in identifying the biological marker most suited to the monitoring of longitudinal tumors.
Genomic profiling of TETs enhances (rather than supplants) the historical histological classification, and should progressively inform therapeutic stratification, particularly in cases of thymic carcinoma.

PMID:
42934010
Bibliographic data and abstract were imported from PubMed on 27 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.